On Demand 2016 Monday General Sessions

You can earn up to 16.75 AMA PRA Category 1 Credit(s). 

This collection covers general sessions from Monday's program. This includes plenaries, symposia, and several workshops. The sessions listed below are included in this package.

  • Immunity Gone Bad
  • Asthma in 2016: Advances in Understanding Origin, Presentation and Approaches to Management
  • W27 - Management of Asthma: Beyond Just Medications
  • W30 - Hyper IgE and Hypereosinophilia: When to Worry and How to Evaluate
  • W33 - Primary Immune Deficiency: Antibiotics and Other Treatments
  • W28 - Atopic Dermatitis In-depth
  • W31 - Delayed Hypersensitivity Drug Reactions: Dilemmas in Diagnosis and Treatment
  • W29 - Alcohol, Marijuana, Hookah and Additive Allergies
  • W32 - Eosinophilic Esophagitis and Other Swallowing Disorders
  • W34 - Allergies in Infants and Very Young Children
  • Modern Therapies for Allergic Skin Diseases

Release Date: 12/01/2016
Expiration Date: 11/30/2019


The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 16.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Learning Objectives

  • Describe the role of viruses and bacteria in asthma inception and how infectious agents could serve as potential targets for asthma prevention
  • Discuss common asthma phenotypes among preschool children and how treatment response to common asthma therapies may be different among these phenotypes
  • Recognize and treat the autoimmune complications of primary immunodeficiency
  • Describe the role of the inflammasome in innate immunity and disease
  • Describe autoimmune complications and auto-inflammatory syndromes and the use of biologics in their treatment
  • Appropriately identify who will benefit from biologic therapy to decrease burden of disease in a cost-effective manner
  • Review some of the evidence for the nonpharmacological (integrative medical) approach to asthma management, including complementary medicine (CM), lifestyle and mind-body strategies
  • Discuss some of the practical and safety issues involved, i.e. exercise, smoking cessation, diet and lifestyle changes
  • Recognize how to offer, present and follow these options to patients using a shared decision-making approach
  • Recognize clinical manifestations of hypereosinophilic disorders
  • Choose appropriate diagnostic tests in the evaluation of hypereosinophilia
  • Interactively discuss a patient with recurrent respiratory infections and the appropriate office evaluation
  • Appreciate the importance of antibiotic prophylaxis in the management of immunodeficiency
  • Recognize the current and evolving treatments for primary immune deficiency
  • Outline an evidence-based therapeutic ladder for management of atopic dermatitis
  • Recognize pitfalls in successful management/ reasons for treatment failure
  • Discuss common delayed drug hypersensitivity reactions presenting to the allergist/immunologist
  • Describe how to perform drug skin testing, including intradermal and patch testing
  • Recognize the clinical symptoms associated with alcohol sensitivity reactions and its evaluation and management
  • Give insight into the health implications of water pipe tobacco smoking/hookah and the use of marijuana
  • Discuss the presenting symptoms associated with food additive allergy
  • Discuss the pathophysiology and differential diagnosis of eosinophilic esophagitis (EoE) and other similar swallowing disorders
  • Discuss the diagnostic options and evolving treatments for EoE
  • Discuss new and current recommendations for diagnosis and management of childhood asthma
  • Apply new and current diagnostic and therapeutic options in respiratory allergies and other conditions in pediatric patients
  • Determine appropriate treatment options and which biologic therapies will benefit patients with atopic dermatitis
  • Discuss the evolving role of the allergist in the diagnosis of contact dermatitis
  • Discuss the approach to patients with pruritus and identify new treatment modalities which will be useful to treat pruritus and other allergic skin diseases
Additional information

Chitra Dinakar, MD, FACAAI -- Consultant/Advisor: Meda, Teva; Speaker: Boehringer Ingelheim, Teva

James Gern, MD -- Consultant/Advisor: Janssen, Prep Biopharma Inc, Regeneron

Leonard B. Bacharier, MD, FACAAI -- Consultant/Advisor: Boehringer Ingelheim, DBV Technologies, Genentech, Meda, Merck, Novartis, Sanofi, Teva, Vectura; Speaker: AstraZeneca, Boehringer Ingelheim, Merck, Teva

John J. Oppenheimer, MD, FACAAI -- Consultant/Advisor: AstraZeneca, Genentech, GlaxoSmithKline, Meda, Mylan, Novartis, Annals of Allergy, ABAI, Up to date, Teva; Supported/ Contracted Research: AstraZeneca, Genentech, MedImmune, Sanofi

Lisa J. Kobrynski, MD, MPH, FACAAI -- Consultant/Advisor: Baxter, CSL Behring; Supported/ Contracted Research: Baxter, Grifols

Hal M. Hoffman, MD -- Consultant/Advisor: Novartis; Speaker: Novartis

Lori Broderick, MD, PhD -- Consultant/Advisor: Novartis, SOBI

Don A. Bukstein, MD, FACAAI -- Speaker: Aerocrine, AstraZeneca, Boston Scientific, Circassia, Faes Farma, Genentech, Meda, Merck, Mylan, Novartis, Stallergenes, Teva

Mark M. Ballow, MD, FACAAI -- Consultant/Advisor: Baxter, Grifols; Speaker: Baxter, CSL Behring; Supported/Contracted Research: CSL Behring, Kedrion, Prometic BioScience

Francisco A. Bonilla, MD, PhD -- Consultant/Advisor: Baxter, CSL Behring, Grifols, Gerson–Lehrman Group, Grand Rounds Health; Patent Holder/Royalty/IPR: UpToDate in Medicine

Mark Boguniewicz, MD, FACAAI -- Consultant/Advisor: Regeneron; Supported/ Contracted Research: Anacor, Regeneron

Peter A. Lio, MD -- Consultant/Advisor: Anacor, Galderma, Johnson & Johnson, IntraDerm Pharmaceuticals, Mission, Exeltis, Pierre Fabre, Regeneron, Valeant; Speaker: Anacor, Mission, Pierre Fabre, Regeneron, Valeant

David A. Khan, MD, FACAAI -- Speaker: Genentech

Eric M. Macy, MD, FACAAI -- Supported/Contracted Research: ALK

Seema S. Aceves, MD, PhD -- Consultant/Advisor: Receptos, Meritage consulting contract now completed

Jonathan M. Spergel, MD, PhD, FACAAI -- Consultant/Advisor: DBV Technologies

Chitra Dinakar, MD, FACAAI -- Consultant/Advisor: Meda, Teva; Speaker: Boehringer Ingelheim, Teva

Todd A. Mahr, MD, FACAAI -- Consultant/Advisor: Meda, Teva; Speaker: Aerocrine, AstraZeneca, GlaxoSmithKline, Meda, Merck, Teva; Supported/Contracted Research: AstraZeneca

Luz S. Fonacier, MD, FACAAI -- Consultant/Advisor: Regeneron, Church and Dwight; Speaker: Baxter;  Supported/Contracted Research: Baxter, Genentech, Merck

Lawrence F. Eichenfield, MD -- Consultant/Advisor: Anacor, Celgene, Genentech, Otsuka, Regeneron, TopMD; Supported/Contracted Research: Astellas, Regeneron

Gil Yosipovitch, MD -- Consultant/Advisor: Anacor, Celgene, Eli Lilly, Johnson & Johnson, Pfizer, Regeneron; Supported/ Contracted Research: Allergan, GlaxoSmithKline, Pfizer, Roche

The following have no financial relationships to disclose:

Hannelore A. Brucker, MD, FACAAI

David R. Naimi, DO

Gailen D. Marshall, MD, PhD, FACAAI

Patricia C. Fulkerson, MD, PhD

Princess Ogbogu, MD

Thomas A. Fleisher, MD, FACAAI

Course summary
Available credit: 
  • 16.75 AMA PRA Category 1 Credit™
  • 16.75 Attendance
  • 4.00 MOC
Course opens: 
Course expires: 

Available Credit

  • 16.75 AMA PRA Category 1 Credit™
  • 16.75 Attendance
  • 4.00 MOC
Please login or create an account to take this course.